A new study on Lyme disease sheds light on the persistence of symptoms; another new study points to an antibiotic that may be ...

Compromised antigen presentation ranks among the top mechanisms that render cancers non-immunogenic (non-responsive to immune ...

Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA signaled it might ...

A novel approach to tumor-infiltrating lymphocyte therapy yielded higher response rates among patients with metastatic ...

In part 4 of an interview with The American Journal of Managed Care®, Frederick L. Locke, MD, provides insight on the design ...

The Mediterranean diet shows promise in managing both systemic and organ-specific autoimmune diseases, including rheumatoid ...

Topas Therapeutics today announced that it will present clinical Phase 2a data on its lead candidate, TPM502, in celiac ...

Alexander Kenigsberg, MD, discusses a new nonsurgical, robotic-focused ultrasound procedure for prostate cancer.

T-cell activation involves two phases, enabling a more precise immune response. This insight may boost cancer immunotherapy ...

New research suggests that lingering cell wall fragments from the Lyme disease bacterium, Borrelia burgdorferi, may be responsible for persistent symptoms long after antibiotic treatment.